Mirae Asset Global Investments Co. Ltd. Has $11.77 Million Stock Position in DexCom, Inc. (NASDAQ:DXCM)

Mirae Asset Global Investments Co. Ltd. raised its stake in DexCom, Inc. (NASDAQ:DXCM) by 13.5% in the 4th quarter, HoldingsChannel reports. The fund owned 147,911 shares of the medical device company’s stock after buying an additional 17,650 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in DexCom were worth $11,768,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Stratos Wealth Partners LTD. acquired a new stake in shares of DexCom in the 4th quarter valued at $201,000. E. Ohman J or Asset Management AB boosted its holdings in DexCom by 12.1% in the fourth quarter. E. Ohman J or Asset Management AB now owns 17,600 shares of the medical device company’s stock valued at $1,369,000 after acquiring an additional 1,900 shares during the last quarter. Alliance Wealth Advisors LLC UT acquired a new stake in DexCom in the fourth quarter worth about $297,000. GDS Wealth Management raised its holdings in DexCom by 17.8% during the 4th quarter. GDS Wealth Management now owns 159,997 shares of the medical device company’s stock worth $12,443,000 after purchasing an additional 24,182 shares during the last quarter. Finally, Jennison Associates LLC lifted its position in DexCom by 10.3% during the 4th quarter. Jennison Associates LLC now owns 7,643,757 shares of the medical device company’s stock valued at $594,455,000 after purchasing an additional 710,858 shares during the period. 97.75% of the stock is owned by institutional investors.

Insider Buying and Selling at DexCom

In other news, EVP Sadie Stern sold 4,259 shares of the business’s stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total value of $318,275.07. Following the sale, the executive vice president now owns 71,192 shares of the company’s stock, valued at $5,320,178.16. The trade was a 5.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, COO Jacob Steven Leach sold 2,634 shares of the firm’s stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $228,920.94. Following the completion of the transaction, the chief operating officer now directly owns 268,644 shares of the company’s stock, valued at approximately $23,347,850.04. This trade represents a 0.97 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 42,342 shares of company stock valued at $3,628,069 in the last 90 days. 0.30% of the stock is currently owned by company insiders.

DexCom Trading Down 0.5 %

DXCM opened at $88.32 on Friday. The stock has a market capitalization of $34.50 billion, a P/E ratio of 52.89, a P/E/G ratio of 2.23 and a beta of 1.14. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00. The firm’s fifty day simple moving average is $81.35 and its 200 day simple moving average is $75.69.

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. Baird R W upgraded shares of DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Leerink Partners lowered their target price on shares of DexCom from $90.00 to $87.00 and set an “outperform” rating for the company in a report on Friday, October 25th. StockNews.com downgraded DexCom from a “buy” rating to a “hold” rating in a research note on Saturday, November 2nd. Redburn Atlantic raised DexCom from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $85.00 to $115.00 in a research note on Monday. Finally, Royal Bank of Canada cut their target price on DexCom from $120.00 to $115.00 and set an “outperform” rating on the stock in a research note on Friday, October 25th. Four equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, DexCom currently has an average rating of “Moderate Buy” and an average price target of $98.41.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.